Detalhe da pesquisa
1.
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
Lancet Oncol
; 25(6): e236-e249, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821098
2.
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.
Eur J Nucl Med Mol Imaging
; 51(4): 1136-1146, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040931
3.
Guiding principles on the education and practice of theranostics.
Eur J Nucl Med Mol Imaging
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38453729
4.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246997
5.
Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients.
Neuroendocrinology
; 112(6): 547-554, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348326
6.
[68Ga]Ga-DATA5m-LM4, a PET Radiotracer in the Diagnosis of SST2R-Positive Tumors: Preclinical and First Clinical Results.
Int J Mol Sci
; 23(23)2022 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36498918
7.
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
Ann Surg
; 274(1): e45-e53, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33030849
8.
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Eur J Nucl Med Mol Imaging
; 48(12): 4067-4076, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34031719
9.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Eur J Nucl Med Mol Imaging
; 48(1): 113-122, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383093
10.
A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.
Int J Med Sci
; 18(10): 2166-2175, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33859524
11.
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.
Lancet Oncol
; 21(9): e431-e443, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888472
12.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med
; 376(2): 125-135, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076709
13.
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Eur J Nucl Med Mol Imaging
; 47(4): 895-906, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838581
14.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Eur J Nucl Med Mol Imaging
; 47(10): 2372-2382, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32123969
15.
Neuroendocrine Neoplasms of the Small Bowel and Pancreas.
Neuroendocrinology
; 110(6): 444-476, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31557758
16.
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Prostate
; 78(11): 775-789, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29717499
17.
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
Eur J Nucl Med Mol Imaging
; 45(7): 1155-1169, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29484451
18.
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases.
Neuroendocrinology
; 106(1): 74-88, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28728155
19.
The ICPO Foundation-on the way toward collaborative growth of theranostics.
Eur J Nucl Med Mol Imaging
; 49(2): 443-444, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984500
20.
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT.
Eur J Nucl Med Mol Imaging
; 43(5): 964-973, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26631238